Myeloid Therapeutics to Present on MT-303, a Pioneering mRNA CAR Targeting GPC3 in Advanced HCC, at SITC 2024.

In 2023, the global market for AAV (Adeno-associated virus) therapies reached $1.5 billion, with projections suggesting growth to $22.3 billion by 2029.

OncoResponse Reports Phase 1 Findings of OR502, an anti-LILRB2 Antibody, in Patients with Advanced Cancer.

Eteplirsen, developed by Sarepta Therapeutics, is an antisense oligonucleotide that targets the dystrophin gene.

Harbour BioMed has filed an IND application for HBM9378/SKB378 to treat chronic obstructive pulmonary disease.

Elacestrant hydrochloride is a small molecule drug that targets ERα and is used in the treatment of various therapeutic areas.

SystImmune, Inc. has received FDA approval for the IND application of BL-M17D1 targeting advanced solid tumors.

Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR).

Nammi Therapeutics, Inc. has reported the first patient has received QXL138AM in a Phase 1 trial focused on advanced solid tumors and multiple myeloma.

Orforglipron is a small molecule drug that targets the GLP-1R, with therapeutic applications in Nervous System Diseases.

Pheast Shares Latest Preclinical Findings on PHST001, an Anti-CD24 Checkpoint Inhibitor for Macrophages, at SITC 2024.

Eplontersen, is an antisense oligonucleotide developed by Ionis Pharmaceuticals and Akcea Therapeutics.